You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Regimens

9 Items
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Mar 2024
Cancer Type:
Breast, 
Endocrine, 
Adrenal, 
Neuroendocrine, 
Pancreatic Neuroendocrine, 
Parathyroid, 
Thymoma, 
Thyroid, 
Gastrointestinal, 
Anus, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Gastrointestinal Stromal Tumours, 
Hepatobiliary / Liver / Bile Duct, 
Mesothelioma (Peritoneal), 
Neuroendocrine (GI), 
Pancreas, 
Rectal, 
Small bowel and appendix, 
Genitourinary, 
Bladder / Urothelial, 
Penile, 
Prostate, 
Renal cell / Kidney, 
Testis, 
Gynecologic, 
Cervix, 
Endometrial, 
Germ Cell, 
Gestational Trophoblastic Disease, 
Ovary, 
Uterine Sarcoma, 
Vagina, 
Vulva, 
Head and Neck, 
Larynx, 
Nasopharynx, 
Oral, 
Paranasal Sinus, 
Pharynx, 
Salivary Gland, 
Squamous Cell, 
Lung, 
Neuroendocrine (Lung), 
Non-Small Cell, 
Small Cell, 
Mesothelioma, 
Ocular / Eye, 
Sarcoma, 
Desmoid Tumour, 
Ewing's, 
Ewing's and Soft Tissue, 
GIST, 
Giant Cell Tumour, 
Kaposi's Sarcoma, 
Osteogenic / Bone, 
Soft Tissue, 
Uterine, 
Wilm's Tumour, 
Skin, 
Basal Cell, 
Melanoma, 
Merkel Cell, 
Squamous Cell, 
Unknown Primary
Intent: Palliative
Funding:
Exceptional Access Program
    entrectinib - Treatment of patients with unresectable locally advanced, or metastatic solid extracranial tumours documented to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, according to specific criteria
Mar 2024
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Apr 2022
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2021
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of metastatic renal cell carcinoma (mRCC) as second or third line therapy in patients
    previously treated for mRCC with a funded tyrosine kinase inhibitor (TKI), with specific criteria
Mar 2023
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Dec 2019